Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 17/20 | 0.63 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228314 | 0.92 | PDE7A (0.65) | PDE7APDE7BPDE4D | |
| SCHEMBL5230910 | 0.90 | PDE7A (0.68) | PDE7APDE7BPDE4D | |
| SCHEMBL27541438 | 0.87 | PDE7A (0.69) | PDE7APDE7BPDE4D | |
| SCHEMBL5228431 | 0.87 | PDE7A (0.69) | PDE7APDE7BPDE4D | |
| SCHEMBL5227949 | 0.87 | PDE7A (0.69) | PDE7APDE7BPDE4D | |
| SCHEMBL5228096 | 0.86 | PDE7A (0.68) | PDE7APDE7BPDE4D | |
| SCHEMBL5229829 | 0.86 | ALDH1A1 (0.52) | PDE7APDE7BKDM4EALDH1A1PDE5A | |
| SCHEMBL5229858 | 0.83 | PDE7A (0.56) | PDE7APDE7BPDE4D | |
| SCHEMBL5237328 | 0.82 | PDE7A (0.70) | PDE7APDE7BPDE4D | |
| SCHEMBL5232195 | 0.81 | PDE7A (0.69) | PDE7APDE7BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | PDE7A 495/4885PDE7B 359/4885KDM4E 2827/4885 |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | PDE7A 4/4885PDE7B 1/4885KDM4E 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.